Blood-based biomarkers for hepatocellular carcinoma screening: Approaching the end of the ultrasound era?
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, in
part because of inadequate early detection strategies. Current recommendations for …
part because of inadequate early detection strategies. Current recommendations for …
Glycosylation markers in cancer
A Silsirivanit - Advances in clinical chemistry, 2019 - Elsevier
Alteration of glycosylation, a hallmark of cancer, results in the production of tumor-
associated glycans or glycoproteins. These molecules are subsequently secreted or …
associated glycans or glycoproteins. These molecules are subsequently secreted or …
[HTML][HTML] Tumor markers for hepatocellular carcinoma
YJ Zhao, Q Ju, GC Li - Molecular and clinical oncology, 2013 - spandidos-publications.com
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with a high
rate of morbidity and mortality. HCC affects approximately one million individuals annually …
rate of morbidity and mortality. HCC affects approximately one million individuals annually …
Risk stratification and early detection biomarkers for precision HCC screening
Hepatocellular carcinoma (HCC) mortality remains high primarily due to late diagnosis as a
consequence of failed early detection. Professional societies recommend semi‐annual HCC …
consequence of failed early detection. Professional societies recommend semi‐annual HCC …
Biomarkers for the early detection of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide, and
the cancer with the fastest increase in mortality in the United States, with more than 39,000 …
the cancer with the fastest increase in mortality in the United States, with more than 39,000 …
[HTML][HTML] Updating the clinical application of blood biomarkers and their algorithms in the diagnosis and surveillance of hepatocellular carcinoma: a critical review
The most common primary liver cancer is hepatocellular carcinoma (HCC), and its mortality
rate is increasing globally. The overall 5-year survival of patients with liver cancer is …
rate is increasing globally. The overall 5-year survival of patients with liver cancer is …
Glycosylation and liver cancer
Liver cancer is the fifth most common cancer, but the second leading cause of cancer death,
in the world, with more than 700,000 fatalities annually. The major etiology of liver cancer is …
in the world, with more than 700,000 fatalities annually. The major etiology of liver cancer is …
[HTML][HTML] Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions
X Li, X Sun, B Wang, Y Li, J Tong - Asian journal of pharmaceutical …, 2023 - Elsevier
Current treatments for advanced hepatocellular carcinoma (HCC) have limited success in
improving patients' quality of life and prolonging life expectancy. The clinical need for more …
improving patients' quality of life and prolonging life expectancy. The clinical need for more …
[HTML][HTML] Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients
BACKGROUND Reliable biomarkers of cirrhosis, hepatocellular carcinoma (HCC), or
progression of chronic liver diseases are missing. In this context, Golgi protein-73 (GP73) …
progression of chronic liver diseases are missing. In this context, Golgi protein-73 (GP73) …
Hepatocellular carcinoma tumour markers: current role and expectations
Tumour markers could be helpful along the continuum of care for patients with
hepatocellular carcinoma; however, there is insufficient data for routine use of most current …
hepatocellular carcinoma; however, there is insufficient data for routine use of most current …